DS
ANIK icon

David Shaw’s Anika Therapeutics ANIK Stock Holding History

David Shaw’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-24,900
Closed -$1.02M – 4159
2014
Q1 		$1.02M Sell
24,900
-51,800
-68% -$1.93M ﹤0.01% 3011
2013
Q4 		$2.93M Buy
76,700
+47,100
+159% +$1.45M ﹤0.01% 2151
2013
Q3 		$709K Buy
+29,600
New +$664K ﹤0.01% 3334

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

David Shaw's ANIK Position: Q2 2026 in Review

David Shaw increased its Anika Therapeutics (ANIK) stake by 6.6% in Q2 2026, buying an estimated $226K and bringing the position to 245,066 shares worth $3.59M. The position accounts for ﹤0.01% of the portfolio, ranked #2688.

David Shaw first reported a position in ANIK in Q2 2013 and has held it in 47 quarters since. The position peaked at $22.4M in Q3 2019. 132 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • David Shaw held 245,066 shares of Anika Therapeutics worth $3.59M as of Q2 2026.
  • David Shaw bought 15,270 Anika Therapeutics shares in Q2 2026, an estimated $226K.
  • Anika Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #2688 holding.
  • David Shaw first reported a position in Anika Therapeutics in Q2 2013 and has held it in 47 quarters since.
  • David Shaw's Anika Therapeutics position peaked at $22.4M in Q3 2019.
  • 132 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.